Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Portfolio Pulse from
Novartis has received European Commission approval for Kisqali® in combination with an aromatase inhibitor for treating HR+/HER2- early breast cancer at high risk of recurrence.
November 27, 2024 | 6:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Kisqali® has been approved by the European Commission for use in HR+/HER2- early breast cancer, potentially increasing its market share and revenue in the oncology sector.
The approval of Kisqali® by the European Commission for a broader patient population in early breast cancer is likely to enhance Novartis' market position in oncology, potentially leading to increased sales and revenue. This regulatory milestone is significant for the company's growth in the European market.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90